Sunesis Pharmaceuticals Inc. (SNSS)

Oncology Corporate Profile

Stock Performance

4.2000
0.0000

HQ Location

395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080

Company Description

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. Sunesis is building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival.

Website: http://www.sunesis.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
vosaroxin / SNS-595topoisomerase 2 inhibitorAcute Myelogenous Leukemia (AML)IIIDainippon Sumitomo
MLN2840Pan-RAF inhibitorMelanomaIIMillennium
vosaroxin / SNS-595topoisomerase 2 inhibitorPlatinum-sensitive Ovarian cancerIIDainippon Sumitomo
MLN2480Pan-RAF inhibitorVarious cancer typesIIMillennium
vosaroxin (+ cytarabine) / SNS-595topoisomerase 2 inhibitorAcute Myelogenous Leukemia (AML)I
SNS-062BTK-inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://www.sunesis.com/

Recent News Headlines

Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting

6/13/2016 12:03 pm

(NASDAQ) June 13, 2016 - Sunesis Pharmaceuticals today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML

3/24/2016 11:21 am

(TheStreet) Mar 24, 2016 - Sunesis Pharmaceuticals, Inc. today announced that the first patients have been treated in the investigator-sponsored VITAL (Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia) Phase 2 study of vosaroxin in combination with cytarabine in patients with previously untreated acute myeloid leukemia (AML).

Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062

3/23/2016 10:57 am

(TheStreet) Mar 23, 2016 - Study start marks Sunesis' second kinase inhibitor program to enter the clinic.

Many Prostate Cancer Patients Saved From Unnecessary Treatments And Side Effects

2/29/2016 12:01 pm

(The Ottawa Hospital [Canada]) Feb 29, 2016 - Low-risk patients increasingly undergoing regular monitoring rather than immediate treatment.

Frozen Section Analysis for Breast Cancer Could Save Time, Anxiety and More Than $90 Million

2/24/2016 11:05 am

(Mayo Clinic) Feb 23, 2016 - When diagnosed with breast cancer, women may have thousands of questions running through their minds, but one they may not have immediately is: Will my choice of provider save me time and money?

Study Identifies New Culprit in Lung Cancer Development

1/29/2016 11:05 am

(VICC) Jan 28, 2016 - A microRNA — a small piece of RNA involved in regulating gene expression — functions as an oncogene to drive the development of lung cancer, Vanderbilt University investigators have discovered.

Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe

12/8/2015 11:34 am

(StreetInsider) Dec 8, 2015 - Sunesis Pharmaceuticals, Inc. today announced that the company has submitted a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Vosaroxin for the treatment of acute myeloid leukemia in patients aged 60 years and older.

Sunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial in AML at ASH Annual Meeting

12/7/2015 05:00 pm

(TheStreet) Dec 7, 2015 - Sunesis Pharmaceuticals, Inc. today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodyplastic syndrome (MDS).

Sunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase 1/2 Trial of Vosaroxin in MDS and VALOR Analysis of Baseline Safety Predictors at ASH Annual Meeting

12/6/2015 02:36 pm

(Sunesis) Dec 6, 2015 - Sunesis Pharmaceuticals, Inc. today announced the presentation of results from a Washington University-sponsored Phase 1 trial of vosaroxin plus azacitidine in patients with myelodysplastic syndrome, and from an analysis of the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in relapsed/refractory acute myeloid leukemia (AML) at the 57th American Society of Hematology Annual Meeting in Orlando, Florida.

Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia

12/3/2015 11:44 am

(Sunesis) Dec 3, 2015 - Sunesis Pharmaceuticals, Inc. today announced that it has initiated a Compassionate Use Program for vosaroxin.

Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End

10/8/2015 12:44 pm

(NASDAQ) Oct 7, 2015 - Sunesis Pharmaceuticals, Inc. today announced that the company intends to submit a Marketing Authorization Application (MAA) for vosaroxin as a treatment for acute myeloid leukemia (AML) with the European Medicines Agency (EMA) by the end of 2015.

New Research Robot Tests Cancer Combinations

9/23/2015 11:05 am

(PharmaTimes [UK]) Sept 23, 2015 - A new smart research robot may be able to accelerate research on cancer medicines by finding optimal treatment combinations.

Counsyl’s New Expanded Inherited Cancer Screen Allows Clinicians to Identify Women at Elevated Cancer Risk Who Would have Otherwise Been Missed

9/23/2015 11:05 am

(Yahoo! Finance) Sept 22, 2015 - Customizable 22-gene cancer panel, on-demand counseling, and streamlined workflow enable clinicians to test and identify more at-risk patients and provide better preventive care.

Cure Forward Launches Precision Medicine Engagement Platform for Cancer Patients

9/23/2015 11:05 am

(MarketWatch) Sept 22, 2015 - Multi-sided technology platform developed to make genomic information usable for consumers and accelerate clinical trial enrollment.

November 19, 2015: Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement

9/23/2015 11:05 am

(FDA.gov) Sept 22, 2015 - Information will be presented to gauge investigator interest in exploring potential pediatric development plans for two products in various stages of development for adult cancer indications. The products under consideration are: (1) ABT-414, submitted by AbbVie, Inc., and (2) Lenvatinib, submitted by Eisai, Inc.

ASCO Applauds IOM Report "Improving Diagnosis in Health Care”

9/23/2015 11:05 am

(ASCO) Sept 23, 2015 - ASCO applauds the Institute of Medicine’s (IOM) new report, Improving Diagnosis in Health Care, released yesterday, and IOM’s continued efforts to improve the quality and safety of healthcare in the United States.

Government Shutdown Showdown

9/23/2015 11:05 am

(ASCO in Action) Sept 22, 2015 - With Congress facing an October 1 deadline to pass the FY16 budget or a continuing resolution to avoid a government shutdown, ASCO is urging lawmakers to reach a budget deal that will expand critical funding for the National Institutes of Health and the National Cancer Institute.

Growing Number of ASCO Members Take Action During August Congressional Recess

9/23/2015 11:05 am

(ASCO in Action) Sept 22, 2015 - Twenty seven ASCO members from California to Florida participated in 30 in-district meetings during the August 2015 Congressional recess to highlight ASCO advocacy priorities related to cancer care.

How the U.S. Could Cure Drug-Price Insanity by Peter B. Bach, MD

9/23/2015 11:05 am

(Fortune) September 15, 2015 Issue - To make sure society keeps benefiting from specialty cancer drugs, we need to curb their soaring costs.

Clinton's Plan To Control Prescription Drug Costs Features Cap On Out-Of-Pocket Expenses

9/23/2015 11:05 am

(KHN Morning Briefing) Sept 23, 2015 - Democratic presidential candidate Hillary Clinton's proposal would also allow Medicare to negotiate lower drug costs and increase federal scrutiny of pharmaceutical company pricing.

Amgen To Present New Kyprolis® (carfilzomib) Data At 15th International Myeloma Workshop

9/23/2015 11:04 am

(CNN Money) Sept 23, 2015 - Additional data from phase 3 ASPIRE trial including age analysis and quality of life results.

Provectus Biopharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial to Study PV-10 in Combination with Immune Check Point Inhibitor Pembrolizumab

9/23/2015 11:04 am

(Stockhouse) Sept 23, 2015 - Provectus Biopharmaceuticals, Inc. today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.

What Cancer Doctors Don’t Know About Cancer Drugs

9/23/2015 11:04 am

(Wall Street Journal) Sept 22, 2015 - “Cancer treatment shouldn’t bankrupt patients” is the gist of an emotional argument put forth by Democratic presidential hopefuls Hillary Clinton and Bernie Sanders.

Merck's Keytruda Tested in Four New Cancers

9/23/2015 11:04 am

(Pharmaphorum [UK]) Sept 22, 2015 - US drugmaker Merck & Co will present data on the use of its PD-1 inhibitor Keytruda in four new cancer types later this week as it jostles for territory in the fast-growing immuno-oncology sector.

Vascular Biogenics Surges for Third Day on Cancer Drug Prospect

9/23/2015 11:04 am

(Bloomberg) Sept 22, 2015 - Vascular Biogenics Ltd., the Israeli biotechnology company that is developing cancer treatments, rallied for a third day on bets it will show promising results from clinical drug trials at a medical conference in Europe this weekend.

Medtronic Testing Lung Cancer Detector (Video)

9/23/2015 11:04 am

(Minneapolis/St. Paul Business Journal) Sept 22, 2015 - Medtronic Inc. has launched a 2,500-patient global study of its SuperDimension system for diagnosing lung cancer.

FDA Seeks More Clinical Evidence On Sunesis Pharma Cancer Drug

7/24/2015 11:06 am

(Reuters) July 23, 2015 - Sunesis Pharmaceuticals Inc said the U.S. Food and Drug Administration called for more clinical evidence before considering approval for its cancer drug, sending the company's shares down 60 percent in after-market trading.

Sunesis Dives as Company Plans to Focus on Getting Qinprezo Approved in EU; FDA Wants New Data

7/24/2015 07:00 am

(Fox Business/Associated Press) July 23, 2015 - Shares of Sunesis Pharmaceuticals plunged in aftermarket trading Thursday after the company said it will focus on trying to get its blood cancer drug Qinprezo on the market in Europe because regulators in the U.S. won't approve it based on available data.

Sunesis Pharmaceuticals Presents New Data From VALOR Evaluating Vosaroxin in Older Patients With Acute Myeloid Leukemia at the 20th Congress of the European Hematology Association

6/12/2015 11:11 am

(StreetInsider) June 12, 2015 - Sunesis Pharmaceuticals, Inc. announced today additional results of the VALOR trial, a Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory acute myeloid leukemia (AML).

Amgen, Novartis Battle in U.S. Court Over Neupogen Copycat

6/4/2015 11:05 am

(Bloomberg) June 3, 2015 - Amgen Inc. and Novartis AG battled in a Washington appeals court Wednesday over when a copycat version of Amgen’s cancer treatment Neupogen can be sold in the U.S., in the first case of its kind.

Statins Could Halve Risk of Dying From Cancer, Says Major Study

6/3/2015 10:04 am

(The Guardian [UK]) June 3, 2015 - Heart attack drugs significantly increased chances of survival from common cancers such as bone, breast, bowel and ovarian, researchers found.

Sunesis Pharmaceuticals Announces Presentation of VALOR Trial Subgroup Analysis at ASCO 2015 Annual Meeting

5/31/2015 06:55 pm

(NASDAQ) May 31, 2015 - Sunesis Pharmaceuticals, Inc. today announced results from a post hoc subgroup analysis of patients age 60 years and older who underwent allogeneic hematopoietic cell transplant (HCT) in the VALOR trial, a Phase 3 study of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML).

MA Therapeutics Achieves Second Major Objective in Collaboration with Celgene Corporation to Advance Innovative Protein Homeostasis Drugs

2/24/2015 12:01 pm

(FORMA Therapeutics) Feb 24, 2015 - FORMA Therapeutics announced today that it has successfully met a second objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene.

ACOG Issues Guidelines for Robot-Assisted Gynecologic Surgery

2/23/2015 12:00 pm

(Medscape Medical News) Feb 23, 2015 - Few data support robot-assisted surgery in gynecologic procedures; the Committee on Gynecologic Practice offers new guidelines.

Study Identifies Promising Drug Target in Certain Breast and Ovarian Cancers

2/18/2015 12:04 pm

(Dana-Farber) Feb 13, 2015 - Study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider – and offers a ready means of identifying them.

First-in Man: Tumor Suctioned From Vein to Allow For Kidney Surgery

2/12/2015 11:05 am

(Henry Ford Health System) Feb 11, 2015 - Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal.

Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting

12/8/2014 05:22 pm

(StreetInsider) Dec 8, 2014 - Sunesis Pharmaceuticals, Inc. today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

NICE Set to Recommend Another Leukaemia Drug

12/2/2014 06:05 am

(NICE) Dec 2, 2014 - NICE has issued further draft guidance for consultation that recommends obinutuzumab, marketed by Roche as Gazyvaro, for some people with untreated chronic lymphocytic leukaemia (CLL).